IF Capital · IPLG tool
Are you ready to raise seed or early capital?
Capital can speed up something that already works. It cannot manufacture a repeatable way to turn strangers into paying customers.
A familiar funding pitch starts with a good idea, a very large market, a clever answer to an incumbent's pricing, and two or three other products the same small team is also building. The ask is money to scale. Most of the time, that is not a funding problem. It is an unproven way of reaching, winning, and serving a paying customer.
Before a funding conversation, one question matters: can the founder point to a specific sequence, from outreach through payment, that turned a stranger into a paying customer more than once, without a relationship only the founder has? If yes, capital may buy speed. If no, capital mostly buys more time to look for the motion.
Why healthcare is less forgiving
Institutional buying does not move faster because a vendor raised a round. A value-analysis committee does not meet sooner. Procurement, security, legal, clinical review, implementation, reimbursement, and renewal still move on their own clocks. The money still leaves a particular budget controlled by a particular person.
That is why a healthcare pilot, letter of intent, or warm introduction is not the same as a repeatable sale. The company has to traverse the real buying path, reach payment, and do it again. Our research on healthcare intermediation and buyer roles shows why the user, approver, purchaser, payer, and economic beneficiary must be named separately.
One team can still be testing several businesses
A product for facilities, a hiring board, a compliance tool, and a regulatory assistant can all be reasonable ideas. They are still four buyers, four budgets, and four sales motions. Early interest in any one of them does not validate the others.
Pick the one with a named buyer and a named budget it can displace. Prove that business first. The rest can wait. Testing four motions at once spreads one team's attention across four unanswered versions of the same question and calls the activity traction.
Proof is cheaper than it used to be
A founder can run careful outreach, close early customers personally, and use AI-assisted research and drafting without first hiring a sales team. That makes the first answer faster and cheaper to obtain. It does not make untested demand more investable.
Raise to accelerate a demonstrated constraint, not to postpone finding out whether a business exists. The assessment below turns that distinction into a decision record you can inspect, challenge, copy, and keep.
Check first
Common traps that look like readiness
These patterns show up in most seed pitches. Each one can feel like evidence until you ask the question underneath it.
Check first
Common traps that look like readiness
These patterns show up in most seed pitches. Each one can feel like evidence until you ask the question underneath it.
Trap 01
A large TAM proves market demand.
The trap: Market-size slides cite decade-out projections, not a reachable buyer with a budget line this year.
The reality: TAM measures aggregate spending. It does not tell you whether a specific institution will pay you, or from which budget.
Self-test: Can I name the person who controls the budget line I expect to displace?
Trap 02
A pilot or letter of intent is the same as a sale.
The trap: Pilots and LOIs often measure interest, not repeatability, procurement, or payment.
The reality: A sale completes the full buying path and payment sequence, then does it again.
Self-test: Do I have a signed contract, an invoice, and a payment record from a stranger?
Trap 03
Founder relationships prove the motion works.
The trap: Warm introductions and personal reputation open doors that will not open for the next hire.
The reality: A repeatable motion works with buyers the founder does not already know.
Self-test: Has the full sequence completed without me personally closing the deal?
Trap 04
Raising money buys runway to find product-market fit.
The trap: Capital extends the calendar, but it does not manufacture a repeatable way to turn strangers into customers.
The reality: Funding buys more of what already works, not more time to look for it.
Self-test: Do I know the exact constraint that new capital would accelerate?
Trap 05
Several products gives us optionality.
The trap: Early teams treat interest in any one idea as validation for all of them.
The reality: Each product is a separate business with its own buyer, budget, and sales motion.
Self-test: Can I name the one product, buyer, and budget I would prove first?
Trap 06
Healthcare buying moves faster once we are funded.
The trap: Founders import consumer-software instincts into an institutional market.
The reality: Committees, procurement, security, legal, clinical review, and reimbursement move on their own clocks. A round does not reset them.
Self-test: Have I mapped the real approval and payment path, not just the clinical champion?
Trap 07
AI makes it cheap to skip early sales work.
The trap: AI can speed up research and drafting, but it cannot replace evidence of paid repeatability.
The reality: Founder-led outreach and early closing are still required to prove the motion works.
Self-test: Have I personally closed the first deals, or has AI only generated materials?
Trap 08
A strong team can sell anything.
The trap: Credentials and past success do not prove this motion works for this buyer.
The reality: Every business has to earn its own evidence of stranger-to-payment repeatability.
Self-test: Can the team show the specific sequence that turned strangers into paying customers?
If any of these traps describe your current evidence, run the cheapest missing test before asking for capital to scale. The assessment below will help you turn the answer into a decision record.
Are you ready to raise?
Before you start, expand Common traps that look like readiness above and read each self-test question. If your current evidence matches a trap, run the cheapest missing test before asking for capital to scale.
Fill out each field from records, not memory. Blank answers stay Unknown. Nothing entered here is stored or sent.
To generate the AI prompt, choose Assess readiness or Argue against the raise, then press Copy prompt. Paste the prompt into your own AI engine, run it against your evidence, and use the output to write a fuller email. When you are ready, press Share non-confidential evidence to send it to us.
Working result
Prove the motion first
The business may be focused, but the record does not yet prove a repeatable, paid motion that works beyond founder-only access. Run the cheapest missing test before raising to scale.
- One business
- Unknown
- Named buyer and budget
- Unknown
- Completed path to payment
- Unknown
- Repeated with strangers
- Unknown
- Not carried by founder-only access
- Unknown
- Real buying path understood
- Unknown
- Current economics recorded
- Unknown
- Capital accelerates proven work
- Unknown
Review the AI prompt
Review the prompt before sharing confidential, personal, patient, or privileged information.
This is a working readiness screen, not investment, legal, or financial advice, and not an offer to invest.
This argument is adapted from Shahid Shah's forthcoming healthcare business-model fieldbook, Doing the Right Thing Is Not a Business Model.